Lilly's Taltz meets in Phase III for TNF inhibitor-experienced ankylosing spondylitis

Eli Lilly and Co. (NYSE:LLY) said Taltz ixekizumab met the primary endpoint of a greater proportion of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at week 16 vs. placebo in the Phase III COAST-W trial to treat ankylosing spondylitis. The company plans to submit a regulatory application to FDA this year to expand the label of Taltz to include treatment of ankylosing spondylitis.

The double-blind, international trial enrolled about 300 patients with ankylosing spondylitis who had an inadequate response or were intolerant to one or two tumor necrosis factor (TNF) inhibitors. Lilly plans to submit detailed data from COAST-W for presentation at scientific meetings this year...